Quadra Assura MP Adverse Events: FDA MAUDE Data

ABBOTT (ST. JUDE MEDICAL) · CRT-Defibrillator (CRT-D) · First cleared Apr 2018 · 8 device variants grouped

Total Reports

10,531

Reports (30d)

41

Active Signals

3

Open Recalls

2

Monthly Report Volume
Event Type Breakdown

Most commonly reported problems

1

Remote Transmission Revealed T-Wave Over-Sensing

transmission revealed, remotely merlin, net review, merlin net, presented remotely

12

reports

2

Remote Presentation with T-Wave Over-Sensing

net, remotely merlin, exhibited post, merlin net, adverse consequences

9

reports

3

Remote Follow-Up Revealed T-Wave Over-Sensing

device technical, exhibited post, observed device, remote follow, support contacted

9

reports

4

MRI Mode Not Programmed, Device in Backup Mode

support contacted, resolve event, technical support, mri, mode

8

reports

5

Infection and Skin Erosion at Device Pocket

right, lead, infection, pocket, ventricular lead

7

reports

6

In-Clinic Follow-Up Revealed T-Wave Over-Sensing

device technical, icd, support contacted, reprogramming, clinic follow

6

reports

Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.

Active safety signals

Disproportionate reportinghighDisproportionate reportinghighDisproportionate reportinghigh

FDA recalls for this device

Class II

Aug 16, 2023 · Open, Classified

Due to Bluetooth malfunction on a subset of Implantable Cardioverter Defibrillator (ICD) and Cardia Resynchronization Therapy Defibrillator *CRT-D) devices that were manufactured prior to April 2022 as a result of crystal component issue within the Bluetooth Low Energy (BLE) circuit. This results in the device entering an inductive telemetry only mode with loss of Bluetooth communication. In some instances, thought BLE communication is unavailable, the circuit may remain in a state which draws excessive power affecting battery longevity.

Class II

Mar 10, 2022 · Open, Classified

Due to a programmer software anomaly under very specific circumstance when executing a pacing capture Decrement Test in-clinic on implantable cardioverter and cardiac resynchronization therapy defibrillator devices, the programmer may continue to execute the Decrement Test instead of terminating the test and restoring the permanent programmed pacing parameters.

Want automated safety signal detection?

Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more. 3 active signals detected right now.

Get Early Access
Disclaimer: This system analyzes publicly available FDA MAUDE data. It does NOT provide medical advice. MAUDE data is de-identified. Do not attempt re-identification. Report counts may differ from the FDA's MAUDE search due to processing cadence and deduplication. Data is updated weekly.